$140.55
0.48%
Nasdaq, Jan 17, 10:25 pm CET
ISIN
US09062X1037
Symbol
BIIB
Sector
Industry

Biogen Stock price

$140.55
-10.09 6.70% 1M
-87.78 38.44% 6M
-12.37 8.09% YTD
-104.72 42.70% 1Y
-98.75 41.27% 3Y
-144.95 50.77% 5Y
-184.37 56.74% 10Y
Nasdaq, Closing price Fri, Jan 17 2025
-0.68 0.48%
ISIN
US09062X1037
Symbol
BIIB
Sector
Industry

Key metrics

Market capitalization $20.48b
Enterprise Value $25.43b
P/E (TTM) P/E ratio 12.70
EV/FCF (TTM) EV/FCF 13.06
EV/Sales (TTM) EV/Sales 2.76
P/S ratio (TTM) P/S ratio 2.22
P/B ratio (TTM) P/B ratio 1.25
Revenue growth (TTM) Revenue growth -3.98%
Revenue (TTM) Revenue $9.23b
EBIT (operating result TTM) EBIT $2.12b
Free Cash Flow (TTM) Free Cash Flow $1.95b
Cash position $1.70b
EPS (TTM) EPS $11.07
P/E forward 11.13
P/S forward 2.12
EV/Sales forward 2.64
Short interest 2.85%
Show more

Create a Free Account to create an Biogen alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Biogen Stock Analysis

Unlock Scores for Free

Analyst Opinions

36 Analysts have issued a Biogen forecast:

19x Buy
53%
17x Hold
47%

Analyst Opinions

36 Analysts have issued a Biogen forecast:

Buy
53%
Hold
47%

Financial data from Biogen

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
9,229 9,229
4% 4%
100%
- Direct Costs 2,975 2,975
3% 3%
32%
6,254 6,254
4% 4%
68%
- Selling and Administrative Expenses 1,703 1,703
14% 14%
18%
- Research and Development Expense 1,803 1,803
19% 19%
20%
2,748 2,748
19% 19%
30%
- Depreciation and Amortization 629 629
6% 6%
7%
EBIT (Operating Income) EBIT 2,119 2,119
23% 23%
23%
Net Profit 1,615 1,615
10% 10%
18%

In millions USD.

Don't miss a Thing! We will send you all news about Biogen directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Biogen Stock News

Neutral
Seeking Alpha
5 days ago
Biogen Inc. (BIIB) J.P. Morgan 43rd Annual Healthcare Conference (Transcript)
Neutral
Reuters
6 days ago
Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional business development deals, the company's CEO said.
Neutral
GlobeNewsWire
7 days ago
LEQEMBI is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration option LEQEMBI is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration option
More Biogen News

Company Profile

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Head office United States
CEO Christopher Viehbacher
Employees 7,570
Founded 1978
Website www.biogen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today